Screening strong anaerobic E. coli promoters to enhance therapeutical protein expression in tumors
Journal of Controlled Release · 2026-11 · 399 · 115407
DOI: 10.1016/j.jconrel.2026.115407 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Controlled Release, 2026-11. Verfasst von Tianqi Cui und 6 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Microbial Technology, Institute of Microbial Technology, Helmholtz International Lab for Anti-infectives, Shandong University…. Hauptthemen laut MEDLINE: Promoter Regions, Genetic, Escherichia coli, Neoplasms. Die Arbeit nennt 54 Literaturangaben. Gefördert von: National Key Research and Development Program of China, Fundamental Research Fund of Shandong University, Key Technologies Research and Development Program.
Abstract (Originalsprache)
Engineered bacterial biotherapeutics have shown increasingly promising potential for cancer treatment, yet they are hindered by unresolved challenges regarding off-target toxicity and suboptimal therapeutic efficacy. In this study, we report the first systematic screening of strong constitutive anaerobic promoters in the probiotic Escherichia coli Nissle 1917 (EcN). Via RNA-seq analysis, we initially identified forty candidate promoters from EcN. Subsequent functional characterization using a firefly luciferase reporter assay yielded six robust constitutive anaerobic promoters, whose activity was 1.18- to 1.85-fold higher than that of Ptac-a strong constitutive promoter traditionally leveraged for therapeutic protein expression in EcN-based cancer biotherapeutics. Further functional validation confirmed that these promoters enable efficient production of immune checkpoint nanobodies, PD-L1nb and CTLA-4nb, in EcN under anaerobic conditions. Notably, in MC38 murine tumor models, EcN-based therapy incorporating these potent constitutive anaerobic promoters achieved significantly enhanced antitumor efficacy compared to conventional promoter-based systems. This not only reinforces the safety profile of engineered EcN but also boosts its therapeutic potency when employed as a tumor-targeted delivery platform in cancer immunotherapy. Collectively, our work establishes a precision delivery framework for potent yet highly toxic anticancer agents, facilitating the development of bacterial biotherapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- State Key Laboratory of Microbial Technology, Institute of Microbial Technology, Helmholtz International Lab for Anti-infectives, Shandong University, Qingdao, Shandong 266237, China.
- Department of Breast Surgery, Qingdao Central Hospital, University of Health and Rehabilitation Sciences, Qingdao, Shandong 266042, China.
- State Key Laboratory of Microbial Technology, Institute of Microbial Technology, Helmholtz International Lab for Anti-infectives, Shandong University, Qingdao, Shandong 266237, China. Electronic address: luanji@sdu.edu.…
- State Key Laboratory of Microbial Technology, Institute of Microbial Technology, Helmholtz International Lab for Anti-infectives, Shandong University, Qingdao, Shandong 266237, China. Electronic address: wanghailong@sdu…
Förderung
- National Key Research and Development Program of China
- Fundamental Research Fund of Shandong University
- Key Technologies Research and Development Program
Zitieren
APA
Cui, T., Yu, G., Jiang, C., Li, L., Mu, Q., Luan, J., & Wang, H. (2026). Screening strong anaerobic E. coli promoters to enhance therapeutical protein expression in tumors. Journal of Controlled Release, 399, 115407. https://doi.org/10.1016/j.jconrel.2026.115407
Vancouver
Cui T, Yu G, Jiang C, Li L, Mu Q, Luan J, et al. Screening strong anaerobic E. coli promoters to enhance therapeutical protein expression in tumors. Journal of Controlled Release. 2026;399:115407. doi:10.1016/j.jconrel.2026.115407
BibTeX
@article{Cui2026,
author = {Cui, Tianqi and Yu, Guangle and Jiang, Chanjuan and Li, Lingdi and Mu, Qiang and Luan, Ji and Wang, Hailong},
title = {Screening strong anaerobic E. coli promoters to enhance therapeutical protein expression in tumors},
journal = {Journal of Controlled Release},
year = {2026},
volume = {399},
pages = {115407},
doi = {10.1016/j.jconrel.2026.115407}
}
EUVIMED